Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2014
10/02/2014WO2014160197A1 Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders
10/02/2014WO2014160181A1 Pyrazole compounds, compositions and methods for treatment of degenerative diseases and disorders
10/02/2014WO2014160102A1 Brain and neural treatments comprising peptides and other compositions
10/02/2014WO2014160077A1 Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor
10/02/2014WO2014159662A1 Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
10/02/2014WO2014159591A1 Substituted 7-azabicycles and their use as orexin receptor modulators
10/02/2014WO2014158998A1 Substituted pyridine and pyrazine compounds as pde4 inhibitors
10/02/2014WO2014158916A1 Substituted naphthyridine and quinoline compounds as mao inhibitors
10/02/2014WO2014158547A1 Compositions for improving cell viability and methods of use thereof
10/02/2014WO2014158165A1 Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell
10/02/2014WO2014158059A1 Method for treating addiction
10/02/2014WO2014157860A1 Process for the preparation of high purity olanzapine and crystalline form ii thereof
10/02/2014WO2014157803A1 Composition comprising shellfish extract as active ingredient which is for anxiety relief, improvement of convulsant, sedative action, or induction or improvement of sleep
10/02/2014WO2014157635A1 Sulfamoylbenzene derivative and drug application
10/02/2014WO2014157569A1 Heterocyclic compound
10/02/2014WO2014157437A1 Propellane derivative
10/02/2014WO2014157380A1 Therapeutic agent for wounds or fibrosis
10/02/2014WO2014157158A1 Phenyl derivative
10/02/2014WO2014157107A1 Polypeptide having sialylated sugar chains attached thereto
10/02/2014WO2014157047A1 Therapeutic agent for neurodegenerative diseases
10/02/2014WO2014155387A1 Extended release dosage forms of quetiapine salts
10/02/2014WO2014155351A1 Stabilized mesembrine compositions
10/02/2014WO2014155332A1 Use of 25-hydroxyvitamin d3 to enhance executive functions
10/02/2014WO2014155186A1 Food supplement for people with down syndrome, autism spectrum disorder and/or attention deficit disorder with or without hyperactivity
10/02/2014WO2014155184A1 Treatment for parkinson's disease
10/02/2014WO2014155056A1 A galactooligosaccharide composition for use in preventing or treating cognitive dysfunction and emotional disturbances in neuropsychiatry illnesses or ageing
10/02/2014WO2014154897A1 NOVEL N-ACYL-(3-SUBSTITUTED)-(8-METHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
10/02/2014WO2014154896A1 NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
10/02/2014WO2014154895A1 NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS
10/02/2014WO2014154179A1 2β,3α,5α-TRIHYDROXY-ANDROST-6-ONE AND PREPARATION METHODS AND USE THEREOF
10/02/2014WO2014154158A1 Traditional chinese medicine composition for treating depression, and preparation method therefor
10/02/2014WO2014154131A1 Caffeoyl substituted pentacyclic triterpene derivative and use thereof
10/02/2014US20140296277 Pharmaceutical preparation containing oxycodone and naloxone
10/02/2014US20140296276 Sequestered antagonist formulations
10/02/2014US20140294876 Amyloid Beta 1-6 Antigen Arrays
10/02/2014US20140294829 Anti-ngf antibodies for the treatment of various disorders
10/01/2014EP2784077A1 Norepinephrine and selective serotonin receptor blocker and use thereof
10/01/2014EP2784068A1 Phosphodiesterase 4 inhibitor capable of avoiding vomiting
10/01/2014EP2784065A1 Glycine reuptake inhibitor and use thereof
10/01/2014EP2783701A2 Extended treatment of multiple sclerosis
10/01/2014EP2783696A1 Phosphorylation on the thr-248 and/or thr-250 residues of transcription factor e2f4 as a therapeutic target in pathological processes associated with somatic polyploidy
10/01/2014EP2783685A1 Use of levo-oxiracetam and oxiracetam in preparation of medicines for preventing or treating coma
10/01/2014EP2782591A1 Lactoferrin and the white matter
10/01/2014EP2782573A1 1,4- dihydropyridine derivatives with hsp modulating activity
10/01/2014EP2782570A1 Heterocyclic inhibitors of glutaminase
10/01/2014EP2782566A1 L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders
10/01/2014EP2782558A1 Immediate release abuse deterrent tablet
09/2014
09/30/2014US8846906 5HT2C receptor modulators
09/30/2014US8846741 N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
09/30/2014US8846735 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
09/30/2014US8846698 Pyrrolo[2,3-d]pyrimidine tropomysin-related kinase inhibitors
09/30/2014US8846696 Purine derivatives
09/30/2014US8846693 Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones
09/30/2014US8846682 Compound suitable for the treatment of synucleopathies
09/30/2014US8846681 Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
09/30/2014US8846663 Modulators of 5-HT receptors and methods of use thereof
09/30/2014US8846409 Methods of preparing cannabinoids from plant material
09/30/2014US8846315 Disease risk factors and methods of use
09/30/2014US8846091 Matrix for sustained, invariant and independent release of active compounds
09/30/2014US8846090 Matrix for sustained, invariant and independent release of active compounds
09/30/2014US8846030 Compounds and methods to enhance rAAV transduction
09/30/2014CA2704279C Method of treating demyelination diseases
09/30/2014CA2655094C Use of pharmaceutical compositions comprising cannabigerol for the treatment of depression
09/25/2014WO2014153529A1 Substituted benzimidazoles as nociceptin receptor modulators
09/25/2014WO2014153226A1 Arginine methyltransferase inhibitors and uses thereof
09/25/2014WO2014153172A1 Pyrazole derivatives as prmt1 inhibitors and uses thereof
09/25/2014WO2014152818A1 Methods of inhibiting cataracts and presbyopia
09/25/2014WO2014152725A1 S1p and/or atx modulating agents
09/25/2014WO2014152621A1 P2x7 modulators
09/25/2014WO2014152589A1 P2x7 modulators
09/25/2014WO2014152537A1 P2x7 modulators
09/25/2014WO2014152444A1 Histone deacetylase inhibitors
09/25/2014WO2014152144A1 Muscarinic agonists
09/25/2014WO2014151752A1 Composition and methods for the treatment of peripheral nerve injury
09/25/2014WO2014151747A1 Methods and compositions with immune therapy for treatment of dementia
09/25/2014WO2014151742A1 Formulation containing carbidopa, levodopa, and entacapone
09/25/2014WO2014151719A1 Sublingual formulations including geranylgeranylacetone and geranylgeranylacetone derivatives
09/25/2014WO2014151697A1 Therapeutic uses for geranylgeranyl acetone and derivatives thereof
09/25/2014WO2014151628A1 Treatment of autism spectrum disorders using helminthic parasite preparations
09/25/2014WO2014151529A1 Therapeutic agents and methods for the treatment of dna repair deficiency disorders
09/25/2014WO2014151387A1 Stable transdermal amphetamine compositions and methods of manufacture
09/25/2014WO2014151338A1 Methods for treating multiple sclerosis
09/25/2014WO2014151258A1 Substituted pyridine derivatives useful as c-fms kinase inhibitors
09/25/2014WO2014150981A1 Inhibitors of lrrk2 kinase activity
09/25/2014WO2014150873A1 Sequestrants of advanced glycation end product (age) precursors
09/25/2014WO2014150687A1 Use of specific carbohydrate systems during pregnancy for improving bone development and formation and/or for improving cognitive and cns development in offspring
09/25/2014WO2014150344A1 C2-azaspiro iminothiazine dioxides as bace inhibitors
09/25/2014WO2014148951A1 Novel therapeutic mirtazapine combinations for use in pain disorders
09/25/2014WO2014148646A1 Pluripotent stem cell for neuronal differentiation induction
09/25/2014WO2014148574A1 Inhibition of production of il-2
09/25/2014WO2014148455A1 Terpenoid derivative
09/25/2014WO2014147636A1 5-amino-quinoline-8-carboxamide derivatives as 5-ht4 receptor agonists
09/25/2014WO2014147353A1 Use of 4-{3-[cis-hexahydrocyclopenta[c]pyrrole-2(1h)-yl]propoxy}benzamide for treating neuropathic pain
09/25/2014WO2014147178A1 Hdac6 inhibitors and uses thereof
09/25/2014WO2014146747A1 Piperazine derivatives as fasn inhibitors
09/25/2014WO2014146699A1 Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities
09/25/2014WO2014146553A1 Flavonoid derivatives and use thereof
09/25/2014WO2014146493A1 Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
09/25/2014WO2014146490A1 Cycloalkyl nitrile pyrazolo pyridones as janus kinase inhibitors
09/25/2014US20140288266 Synthesis of Cyclosporin Analogs
1 ... 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 ... 1833